<DOC>
	<DOCNO>NCT00541970</DOCNO>
	<brief_summary>Human Papillomavirus ( HPV ) infection establish necessary cause cervical cancer . GlaxoSmithKline ( GSK ) Biologicals develop HPV vaccine ( 580299 ) target 2 common oncogenic HPV type ( HPV-16 HPV-18 ) , find approximately 70 % cervical cancer . In previous trial vaccine find efficacious prevention incident persistent HPV-16/18 infection associate cytological abnormality cervical dysplasia . In partially-blind study , GSK Biologicals evaluate safety immunogenicity HPV vaccine use alternative schedule alternative dosing administer healthy young female age 9 25 year , compare standard HPV vaccine . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 . The protocol post update follow protocol amendment .</brief_summary>
	<brief_title>Partially Blind Study Evaluate Immunogenicity &amp; Safety GSK Bio 's HPV Vaccine 580299 Healthy Women Aged 9-25 Yrs</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe and/or parent comply requirement protocol enrol study . A female subject , include , 9 25 year age time first vaccination . Written inform consent/assent obtain subject prior enrolment . For subject legal age consent , write informed consent must obtain subject . For subject legal age consent , write informed consent subject 's parents/legally acceptable representative , write informed assent must obtain subject . Healthy subject establish medical history historyoriented clinical examination enter study . Subject must nonchildbearing potential , childbearing potential , must practice adequate contraception 30 day prior vaccination , negative pregnancy test continue precaution two month completion vaccination series . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period ( Month 24 ) . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Concurrently participate another clinical study , time study period ( Month 24 ) , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Planned administration/administration vaccine foreseen study protocol within 30 day 30 day first dose vaccine . Planned administration/administration routine vaccine , 8 day first dose study vaccine allow . Enrolment defer subject outside specify window . Pregnant breastfeed female . A woman plan become pregnant planning discontinue contraceptive precaution study period , two month last vaccine dose . Previous vaccination HPV plan administration HPV vaccine foreseen study protocol study period ( Month 24 ) . Previous administration component investigational vaccine . Cancer autoimmune disease treatment . Any medically diagnose suspected immunosuppressive immunodeficient condition , base medical history physical examination . History allergic disease reaction likely exacerbate component vaccine . Hypersensitivity latex . Acute disease time enrolment . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory test . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period ( Month 24 ) .</criteria>
	<gender>Female</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>viral infection</keyword>
	<keyword>Human Papillomavirus ( HPV ) vaccine</keyword>
	<keyword>safety</keyword>
	<keyword>vaccine</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>cervical cancer</keyword>
</DOC>